{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T03:52:40Z","timestamp":1781927560984,"version":"3.54.5"},"reference-count":22,"publisher":"Japanese Society of Internal Medicine","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,6,15]]},"DOI":"10.2169\/internalmedicine.6348-25","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T22:06:32Z","timestamp":1761775592000},"page":"1678-1681","source":"Crossref","is-referenced-by-count":1,"title":["Effective Treatment with Ruxolitinib and Ropeginterferon Alfa-2b for Refractory TAFRO-like Syndrome"],"prefix":"10.2169","volume":"65","author":[{"given":"Satoko","family":"Oka","sequence":"first","affiliation":[{"name":"Division of Hematology, Japanese Red Cross Society Wakayama Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuina","family":"Ueda-Akagi","sequence":"additional","affiliation":[{"name":"Division of Hematology, Japanese Red Cross Society Wakayama Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaya","family":"Mitsuyoshi","sequence":"additional","affiliation":[{"name":"Division of Hematology, Japanese Red Cross Society Wakayama Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Ono","sequence":"additional","affiliation":[{"name":"Division of Pathology, Japanese Red Cross Society Wakayama Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Fujimoto S, Sakai T, Kawabata H, et al. Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease? Am J Hematol 94: 975-983, 2019.","DOI":"10.1002\/ajh.25554"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Masaki Y, Kawabata H, Takai K, et al.; Japanese TAFRO Syndrome Research Team. 2019 Updated diagnostic criteria and disease severity classification for TAFRO syndrome. Int J Hematol 111: 155-158, 2020.","DOI":"10.1007\/s12185-019-02780-1"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Pierson SK, Shenoy S, Oromendia AB, et al. Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease. Blood Adv 5: 3445-3456, 2021.","DOI":"10.1182\/bloodadvances.2020004016"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. de Weerd NA, Samarajiwa SA, Hertzog PJ. Type I interferon receptors: biochemistry and biological functions. J Biol Chem 282: 20053-20057, 2007.","DOI":"10.1074\/jbc.R700006200"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Billiau A. Interferon: the pathways of discovery: I. molecular and cellular aspects. Cytokine Growth Factor Rev 17: 381-409, 2006.","DOI":"10.1016\/j.cytogfr.2006.07.001"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Gilbert HS. Long term treatment of myeloproliferative disease with interferon-\u03b1-2b: feasibility and efficacy. Cancer 83: 1205-1213, 1998.","DOI":"10.1002\/(SICI)1097-0142(19980915)83:6<1205::AID-CNCR21>3.0.CO;2-8"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kiladjian JJ, Zachee P, Hino M, et al. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. Lancet Haematol 7: e226-e237, 2020.","DOI":"10.1016\/S2352-3026(19)30207-8"},{"key":"8","unstructured":"8. Gisslinger H, Klade C, Georgiev P, et al.; PROUD-PV Study Group. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol 7: e196-e208, 2020."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Gisslinger H, Klade C, Georgiev P, et al.; PROUD-PV Study Group. Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment. Leukemia 37: 2129-2132, 2023.","DOI":"10.1038\/s41375-023-02008-6"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Kirito K, Sugimoto Y, Gotoh A, et al. Long-term safety and efficacy of ropeginterferon alfa-2b in Japanese patients with polycythemia vera. Int J Hematol 120: 675-683, 2024.","DOI":"10.1007\/s12185-024-03846-5"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Kawabata H, Fujimoto S, Sakai T, et al. Patient&apos;s age and D-dimer levels predict the prognosis in patients with TAFRO syndrome. Int J Hematol 114: 179-188, 2021.","DOI":"10.1007\/s12185-021-03159-x"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Igawa T, Sato Y. TAFRO syndrome. Hematol Oncol Clin North Am 32: 107-118, 2018.","DOI":"10.1016\/j.hoc.2017.09.009"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Wakiya R, Kameda T, Takeuchi Y, et al. Sequential change in serum VEGF levels in a case of tocilizumab-resistant TAFRO syndrome treated effectively with rituximab. Mod Rheumatol Case Rep 5: 145-151, 2021.","DOI":"10.1080\/24725625.2020.1789304"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Kikuchi T, Shimizu T, Toyama T, Abe R, Okamoto S. Successful treatment of TAFRO syndrome with tocilizumab, prednisone, and cyclophosphamide. Intern Med 56: 2205-2211, 2017.","DOI":"10.2169\/internalmedicine.8522-16"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Williams C, Phillips A, Aggarwal V, Slonim LB, Fajgenbaum DC, Karmali R. TAFRO syndrome and elusive diagnosis of idiopathic multicentric Castleman disease treated with empiric anti-interleukin-6 therapy. Case Rep Oncol 14: 1359-1365, 2021.","DOI":"10.1159\/000518079"},{"key":"16","doi-asserted-by":"crossref","first-page":"e135031","DOI":"10.1172\/jci.insight.135031","volume":"5","author":"RL Pai","year":"2020","unstructured":"16. Pai RL, Japp AS, Gonzalez M, et al. Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease. JCI Insight 5: e135031, 2020.","journal-title":"JCI Insight","ISSN":"https:\/\/id.crossref.org\/issn\/2379-3708","issn-type":"print"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM. JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs 77: 521-546, 2017.","DOI":"10.1007\/s40265-017-0701-9"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Lust H, Gong S, Remiker A, Rossoff J. Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL-6\/JAK inhibition: a pediatric case series. Pediatr Blood Cancer 68: e29261, 2021.","DOI":"10.1002\/pbc.29261"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Killian M, Viel S, Chalayer E, et al. JAK1\/2 inhibition in severe TAFRO syndrome: a case report. Ann Intern Med 174: 719-721, 2021.","DOI":"10.7326\/L20-1051"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Regimbeau M, Mary R, Hermetet F, Girodon F. Genetic background of polycythemia vera. Genes (Basel) 13: 637, 2022.","DOI":"10.3390\/genes13040637"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Tefferi A, Barbui T. Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol 98: 1465-1487, 2023.","DOI":"10.1002\/ajh.27002"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22. Bewersdorf JP, Giri S, Wang R, et al. Interferon alpha therapy in essential thrombocythemia and polycythemia vera - a systematic review and meta-analysis. Leukemia 35: 1643-1660, 2021.","DOI":"10.1038\/s41375-020-01020-4"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/12\/65_6348-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T03:37:35Z","timestamp":1781926655000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/12\/65_6348-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6348-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"article-number":"6348-25"}}